anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a Chinese medicinal composition for treating liver carbuncle. The Chinese medicinal composition is prepared from the following raw material medicaments in part by weight: 8 to 15 parts of Chinese lobelia herb, 10 to 20 parts of barbed skullcap herb, 25 to 35 parts of spreading hedyotis gerb, 25 to 35 parts of motherwort herb, 25 to 35 parts of virgate wormwood herb, 25 to 35 parts of whiteflower patrinia herb and 8 to 15 parts of shinyleaf pricklyash root. The compatibility thought of the Chinese medicinal composition is that the Chinese lobelia herb, the virgate wormwood herb and the shinyleaf pricklyash root are used as monarch medicaments; the barbed skullcap herb, the spreading hedyotis gerb and the whiteflower patrinia herb are used as ministerial medicaments; and the motherwort herb is used as an adjuvant. The Chinese medicinal composition fulfils the aim of treating the liver carbuncle by clearing away heat and toxic materials and protecting livers and gallbladders. Liquor is prepared by boiling medicaments of the Chinese medicinal composition in water by a conventional method and the medicaments can be also prepared into powder, tablets and capsules by the conventional method. The Chinese medicinal composition for treating the liver carbuncle has the advantages of unique compatibility, skillful medicament combination, obvious effect of treating the liver carbuncle, good curative effect, low treatment cost and no side effect.
Cyclic vomiting syndrome (CVS) is a disorder characterized by recurrent and unpredictable episodes of intense vomiting, interspersed with periods of apparent wellbeing. This disorder, which primarily affects children and adolescents but can persist into adulthood, has recently been the subject of extensive study and analysis in the medical literature. The aim of the present review is to examine the most important aspects of the epidemiology, pathophysiology, subtypes, diagnostic criteria, and current management of CVS. Even though the exact etiology remains unknown, genetic factors (polymorphisms), nervous system alterations and autonomic dysregulation, and environmental factors (use and abuse of cannabinoids) are postulated as possible triggers. CVS has significant diagnostic challenges, given that there is no specific test for confirming its presence. Thorough evaluation of symptoms and the ruling out of other possible causes of recurrent vomiting are required. Management of CVS typically involves a multidisciplinary approach. Pharmacologic options are explored, such as antiemetics and preventive medications, as well as behavioral and psychologic support therapies. Treatment personalization is essential, adapting it to the individual needs of each patient. Despite advances in the understanding of CVS, it remains a significant clinical challenge. This disorder impacts the quality of life of those affected and their families, underscoring the ongoing need for research and the development of more effective treatment strategies.
The patient was an 86-year-old woman. She was brought to the emergency department because of chest pain and respiratory distress symptoms that did not improve. 12-lead electrocardiogram, echocardiography, and blood tests were negative for acute coronary syndrome, but a chest contrast computed tomography( CT) -scan showed pericardial effusion and a coronary artery aneurysm 20 mm in diameter, and punctured pericardial effusion revealed bloody fluid. A cardiac catheterization was performed. He underwent emergent surgery after being diagnosed as having a ruptured coronary aneurysm associated with a coronary pulmonary artery fistula. The aneurysm was dissected using cardiopulmonary bypass, and the coronary artery-pulmonary artery fistula was closed. The patient had a good postoperative course and was discharged in good condition. There have been few reports of rupture when the aneurysm diameter is less than 30 mm. Regardless of the size of the aneurysm, it has a risk of rupture and it is important to consider surgery.
Drug eluting stented tubular grafts wherein the stent is coated with a coat comprising a composite of at least one biocompatible, pharmaceutically acceptable, bioerodible polymer and at least one therapeutic substance. The polymer may be a polyester. The therapeutic agent may include selective gene delivery vectors, sirolimus, actinomycin-D and paclitaxel. The stented grafts include an integrally stented embodiment and an internally stented embodiment. In each embodiment, the stent may be either self-expanding or pressure-expandable. Further, the stent may comprise a plurality of elements, wherein each said element comprises an undulating linear shape formed into a generally cylindrical configuration, and wherein each said element is connected to an adjacent neighbor element by at least one linear connector. A method for the treatment of cardiovascular disease by implantation of the stented graft, and an article of manufacture, comprising packaging material and the stented graft are also taught.
Injections of placebo were made into each 1 of 5 fat pads. The total injection volume into each fat pad was 1 mL. One-time treatment.
We describe an improved method for generating sizable numbers of mature dendritic cells from nonproliferating progenitors in human blood. The first step or "priming" phase is a culture of T cell depleted mononuclear cells in medium supplemented with GM-CSF and IL-4 to produce immature dendritic cells. The second step or "differentiation" phase requires the exposure to dendritic cell maturation factor such as monocyte conditioned medium. Using this two-step approach, substantial yields are obtained. The dendritic cells derive from this method have all the features of mature cells. They include a stellate cell shape, nonadherence to plastic, and very strong T cell stimulatory activity. The mature dendritic cells produced according to this invention are useful for activating T cells.
<P>PROBLEM TO BE SOLVED: To provide a cosmetic stably comprising capillarisin over a long period of time and having excellent feeling of use and bleaching effects.  <P>SOLUTION: The cosmetic comprises (A) the capillarisin and (B) amines or an acid addition salt thereof at pH3-5.5. In the cosmetic, the capillarisin or Artemisia capillan's Thunb. containing the capillarisin or an extract thereof is used as the ingredient (A). The feeling of use is excellent and sediments readily forming especially when using the extract of the Artemisia capillan's Thunb. can be inhibited by using the amines or the acid addition salt thereof of the ingredient (B).  <P>COPYRIGHT: (C)2008,JPO&INPIT
Stricture formation leading to obstruction in Crohn's disease (CD) remains one of the largest unmet needs in the field of inflammatory bowel diseases (IBD). Despite this need no selective anti-stricture drug has been approved for use in CD patients. This contrasts with other fibrotic diseases, such as in the lung, liver or kidney, where multiple drug development programs crossed the starting line and two anti-fibrotics are now being approved for pulmonary fibrosis. Strictures are composed of a mix of inflammation, excessive deposition of extracellular matrix (ECM) and smooth muscle hyperplasia, likely all ultimately being responsible for the luminal narrowing driving patient symptoms. Our understanding of the pathogenesis of stricturing CD has evolved and indicates a multifactorial process involving immune and non-immune cells and their soluble mediators. This understanding has rendered target pathways for anti-stricture drug development. Significant progress was made in creating consensus definitions and tools to enable clinical trials with two clinical development programs having been conceived to date. In this chapter, we discuss stricture pathogenesis with a focus on the pathways being tested in clinical trials, and clinical trial endpoints developed for this indication.
PURPOSE:To obtain an aerosol composition alcohol containing a polyhydric alcohol in a large amount more than a definite value as a stock solution and containing a nonsteroidal antiphlogistic external preparation as an active ingredi ent, free from irritation to nasal mucosa due to foamy or gel-like form in spraying and capable of improving blood circulation. CONSTITUTION:The objective aerosol composition contains >=70wt.% polyhydric alcohol as a stock solution and contains preferably about 0.1-5% nonsteroidal antiphlogistic external preparation. As the polyhydric alcohol, e.g. glycerol, propylene glycol, 1,3-butylene glycol or polyethylene glycol is especially preferably used, because it is high in safety to human body and acts also as humectant. 0.1-20% foam stabilizer and/or gelling agent and about 10% auxiliary agent are preferably further added to the stock solution. The nonsteroidal antiphlogistic external preparation includes e.g. bufexamac, ibuprofen, indomethacin or piroxicam. The aerosol composition consists of 80-98% stock solution and 2-20% liquefied gas (propellant) or 95-99.5% stock solution and 0.1-5% compressed gas (propellant).
Viruses have developed many mechanisms by which they can stimulate or inhibit inflammation and cause various diseases, including viral respiratory diseases that kill many people every year. One of the mechanisms that viruses use to induce or inhibit inflammation is exosomes. Exosomes are small membrane nanovesicles (30-150 nm) released from cells that contain proteins, DNA, and coding and non-coding RNA species. They are a group of extracellular vesicles that cells can take up to produce and mediate communication. Intercellular effect exosomes can deliver a broad confine of biological molecules, containing nucleic acids, proteins, and lipids, to the target cell, where they can convey therapeutic or pathogenic consequences through the modulation of inflammation and immune processes. Recent research has shown that exosomes can deliver entire virus genomes or virions to distant target cells, then the delivered viruses can escape the immune system and infect cells. Adenoviruses, orthomyxoviruses, paramyxoviruses, respiratory syncytial viruses, picornaviruses, coronaviruses, and rhinoviruses are mostly related to respiratory diseases. In this article, we will first discuss the current knowledge of exosomes. We will learn about the relationship between exosomes and viral infections, and We mention the inflammations caused by viruses in the airways, the role of exosomes in them, and finally, we examine the relationship between the viruses as mentioned earlier, and the regulation of inflammatory pathways that play a role in causing the disease.
LOLA will be administered via continuous intravenous infusion at a dosage of 0.75g/kg/day for 72h (maximum 30g/day). High volume plasma exchange (2x plasma volume) will be started at least 8 hours after initiation of LOLA, and will be completed within 4-5 hours depending on the volume of exchange. Three consecutive cycles of HVPE will be performed, starting at 8h, 32h and 56h respectively.
Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
BACKGROUND: Most of the worldwide population is overweight and suffers from the resulting musculoskeletal comorbidities such as knee osteoarthritis or back pain. Practice guidelines recommend weight loss interventions for individuals suffering from these conditions. This systematic review investigated whether including a weight loss intervention in the musculoskeletal therapy of these individuals was cost-effective compared to administering the musculoskeletal therapy alone.
METHODS: This study followed the PRISMA guidelines to systematically and independently search six databases and select full health economic evaluations published up to May 2024 from health care or societal perspectives according to predefined eligibility criteria. Cost data were standardised to 2023 Belgium Euros. The methodological quality was assessed using two health economic-specific checklists.
RESULTS: The searches produced 5'305 references, of which 8 studies were selected for a total of 1'726 participants. The interventions consisted of different exercise plans and nutritional targets. Six values were in the north-eastern; leading to increased quality-adjusted life year (QALY) and higher costs; and two in the south-eastern quadrant of the cost-utility plane; leading to increased QALYs and lower costs. Two studies observed no differences in QALYs. Incremental cost utility ratios (ICUR) ranged from €13'580.10 to €34'412.40 per additional QALY from a healthcare perspective. From a societal perspective, the ICUR was €30'274.84. The included studies fulfilled 86 percent of the criteria in trial-based economic evaluations and 57 percent in model-based economic evaluations. The most common limitations of the studies were related to appropriate cost measures' specifications, research questions, time horizon choices, and sensitivity analyses.
CONCLUSIONS: This systematic review showed weak but consistent evidence of cost-effectiveness for adding a weight loss intervention to musculoskeletal therapy for individuals with overweight, from either perspective. Further economic evaluations should evaluate the long-term cost-effectiveness of the intervention.
TRIAL REGISTRATION: International Platform of Registered Systematic Review and Meta-analysis Protocols INPLASY (2022,110,122).
Patients who have experienced an OOD in the past 8 months will be eligible to receive TTIP-PRO. A letter about the study will be sent to those patients. Interested patients will call the UC Health staff working on this study. The intervention entails administering the Personal Opioid-Overdose Risk Survey and the Opioid Overdose and Treatment Awareness Survey to the patient. The TTIP-PRO computer program uses the information to generate the "Personal Feedback Report", which is used by the Peer Interventionist to provide the intervention. The TTIP-PRO computer program also creates the "Personal Risk Factors Report" which is mailed to the participant with some other helpful information.
Administer Albuterol Sulfate HFA by oral inhalation only. Shake well before each spray. To maintain proper use of this product and to prevent medication build-up and blockage, it is important to follow the cleaning directions carefully.

Priming: Prime the inhaler before using for the first time and in cases where the inhaler has not been used for more than 2 weeks by releasing three sprays into the air, away from the face.

Cleaning: As with all HFA-containing albuterol inhalers, to maintain proper use of this product and to prevent medication build-up and blockage, it is important to clean the plastic mouthpiece regularly. The inhaler may cease to deliver medication if the plastic actuator mouthpiece is not properly cleaned and dried. To clean: Wash the plastic mouthpiece with warm running water for 30 seconds, shake off excess water, and air dry thoroughly at least once a week. If the patient has more than one Albuterol Sulfate HFA inhaler, the patient should wash each one separately to prevent attaching the wrong canister to the wrong plastic actuator. In this way, the patient can be sure to always know the correct number of remaining doses. Never attach a canister of medication from any other inhaler to the Albuterol Sulfate HFA actuator and never attach the Albuterol Sulfate HFA canister to an actuator from any other inhaler. If the mouthpiece becomes blocked, washing the mouthpiece will remove the blockage. If it is necessary to use the inhaler before it is completely dry, shake off excess water, replace canister, spray twice into the air away from face, and take the prescribed dose. After such use, the mouthpiece should be rewashed and allowed to air dry thoroughly. [see FDA-Approved Patient Labeling (17.9)].

Dose Counter: Albuterol Sulfate HFA has a dose counter attached to the actuator. When the patient receives the inhaler, a black dot will appear in the viewing window until it has been primed 3 times, at which point the number 200 will be displayed. The dose counter will count down each time a spray is released. When the dose counter reaches 20, the color of the numbers will change to red to remind the patient to contact their pharmacist for a refill of medication or consult their physician for a prescription refill. When the dose counter reaches 0, the background will change to solid red. Albuterol Sulfate HFA inhaler should be discarded when the dose counter displays 0 or after the expiration date on the product, whichever comes first.
The proposed study is a prospective, multi-center, two-arm, randomized, crossover design to be conducted at up to 10 sites. The study will enroll up to 100 subjects in order to include up to 10 subjects in the study per site. Subjects selected to participate in the trial have back and/or leg pain, have been evaluated as a candidate for SCS and have agreed to undergo a temporary SCS trial using the Algovita® system with percutaneous leads. Each subject will be followed during the trial period of approximately 7+/-2 days. The study will end when the last subject has completed the trial period and exited. The expected enrollment period for this study is approximately six months. After exit from the clinical study, subjects will continue to be followed by their physician per usual care. All device and procedure-related AEs will be collected and reported per the study protocol.
Participants will receive treatment A (Loperamide therapeutic dose) on Day 1 on treatment period 1, followed by Treatment D (Moxifloxacin) on Day 1 of treatment period 2 followed by Treatment B (Loperamide supratherapeutic dose) on Day 1 of treatment period 3 followed by Treatment C (placebo) on Day 1 of treatment period 4. Each treatment period will be separated by a minimum of 7-day washout period and no more than 21-day.
BACKGROUND AND AIMS: Progression to hepatocellular carcinoma (HCC) is restricted by viral suppression in chronic hepatitis B (CHB); however, some patients still progress despite antiviral therapy. Presence of single nucleotide polymorphisms (SNPs) such as PNPLA3 rs738409 and TM6SF2 rs58542926 are associated with the development and progression of steatotic liver disease to HCC, whereas a splice variant in HSD17B13 rs72613567:TA has been shown to be protective. We investigated the role of these SNPs in the development or prognosis of HCC in pure CHB etiology, in the absence of hepatic steatosis, remains unknown.
MATERIALS: We analysed PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 SNPs in a prospectively recruited cohort (n=323) consisting of healthy controls, CHB and CHB-HCC patients without hepatic steatosis. SNPs were determined by PCR analysis and associations for the alleles and genotypes were investigated using adjusted-logistic regression analyses. The overall survival (OS) data were collected from CHB-HCC patients for survival analysis.
RESULTS: The genotype and allelic distribution of PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 were similar between healthy controls, CHB, and CHB-HCC groups. No genotype, allele or haplotype analysis was found to be associated with increased risk for CHB-HCC. Survival analysis revealed no genotype or allele to be associated with OS in patients with CHB-HCC.
CONCLUSIONS: We could not demonstrate any association of PNPLA3 rs738409, TM6SF2 rs58542926, and HSD17B13 rs72613567 with the development or prognosis of CHB-HCC, supporting the initial hypothesis that they should be considered specific hotspots for liver diseases characterized with hepatic steatosis.
A remote intelligent cunguan chi pulse diagnosis device is a remote application of an artificial intelligent bionic robot for realizing the technology of Chinese medical inspection, smelling, inquiry and diagnosis. The hand vein terminal and the consultation terminal are arranged. The hand vein terminal is provided with 3 fingertip tactile sensors which respectively touch the cunguan chi part, and the consultation terminal is provided with three finger plates. The pulse feeling action drives 3 finger tips of the pulse feeling terminal to simulate corresponding action by the change signal of the force applied by touching the three finger disks by the fingers. The cun-guan-chi waveforms of the diagnosed person are synchronously displayed on the screens of the two terminals, and the pulse feeling visualization is realized. The two terminals are communicated to realize the functions of inspection and diagnosis. The nanometer nose arranged at the hand pulse terminal realizes the function of auscultation. All the diagnosis information can be stored in the terminal and the cloud end at the same time, and an artificial intelligence ecological mode with an autonomous learning function is set, so that real-time upgrading of cloud traditional Chinese medicine is realized. The traceability, revenue and protection of the generated data assets are realized by adopting a block chain technology. Promotes the practical popularization of health science mainly based on the prevention of Chinese medicine.
Subjects participating in this observational study originally participated in CS10BR05 Inj. phase 1 study.
INTRODUCTION: Group psychoeducation is effective in preventing relapse in bipolar disorder. It's indicated as an adjunctive intervention to pharmacotherapy for all outpatients. This retrospective, single center experience of group psychoeducation for bipolar disorder over a 6 years period, aims to assess severity of symptoms and comparative relapse episodes and intensity prior to and following psychoeducation as well as evaluating the decrease in hospitalizations and days of hospitalization.
METHODS: Between 2014 and 2019 patients with a bipolar disorder were invited to attend a Colom model group psychoeducation (weekly 90 minutes sessions for 22 weeks). Depression and mania were assessed at baseline, following psychoeducation, 6 months and 12 months with the Hamilton Depression Rating Scale (HDRS) and Young Mania Rating Scale (YMRS). Patient specific hospitalization admissions data for 3 years prior to and 3 years following psychoeducation course were accessed. Subgroup analyses were performed according to patient sex and age with ANOVA methodology.
RESULTS: Of the 95 eligible patients, 77 completed psychoeducation: 18 (19%) patients dropped out. Mean patient age was 45 years and 33 (43%) were male. Overall and subgroup specific YMRS and HDRS improved significantly throughout follow-up (p<0.01). Hospitalization analyses (45 patients; 58.4%) revealed a significant decrease in relapse and hospital stay days after psychoeducation, p<0.01.
DISCUSSION: We provide evidence of applicability and efficacy of adjunctive psychoeducation in a real-world setting. Advantages observed were independent of patient sex and age. Analysis of the optimal number of sessions provided to patients according to efficacy and retention rates is required.
CONCLUSIONS: Despite inherent study design limitations, retrospective evaluation of a single-center psychoeducation program supports evidence of psychoeducation effectiveness in significantly reducing the severity of bipolar disorder and hospitalizations, despite a drop-out rate of 1 in 5.
FIELD: cosmetics. SUBSTANCE: composition for oxidizing coloring of hair contains 2-chlorine-6-methyl-3-aminophenol in combination with oxidizing base and additional binding agent selected from m-aminophenols and m-phenylenediamines. The subject of invention also involves method of hair coloring and packaging of set for coloring. The proposed composition ensures rich coloring of various tones and it is stable to atmospheric factors. EFFECT: higher efficiency. 27 cl, 6 tbl, 6 ex